CD274 and neoplasm: The OS was investigated by a hierarchical statistical analysis aimed previously at the prespecified population of patients with tumors overexpressing PD-L1 or with at least 5% PD-L1 expression on tumor-infiltrating immune cells (ICs) (defined as IC2/3), who represented 25% of the overall study population.8